Janssen Biotech Bolsters Immuno-Oncology Pipeline with Xencor’s Bispecific Antibodies
By Lucy Haggerty
Pharma Deals Review: Vol 2021 Issue 10 (Table of Contents)
Published: 19 Oct-2021
DOI: 10.3833/pdr.v2021.i10.2641 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In order to strengthen its immuno-oncology pipeline, Janssen Biotech has agreed to pay US$100 M upfront and committed up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS